ArticleEuropean heart journal2012
Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?
Article in European heart journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).European journal of heart failure · 2018Trial
- Recurrent events analysis for examination of hospitalizations in heart failure: insights from the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) trial.European heart journal. Quality of care & clinical outcomes · 2018Trial
- Remote Management of Patients With Heart Failure in Medically Underserved Areas.JACC. Advances · 2026Article
- Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.Journal of neurology · 2025Review
- Defining estimand for the win ratio: Separate the true effect from censoring.Clinical trials (London, England) · 2024Article
- The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development.JACC. Basic to translational science · 2024Review
- Recurrent heart failure hospitalizations in heart failure with preserved ejection fraction: an analysis of TOPCAT trial.ESC heart failure · 2024Article
- Dissecting the restricted mean time in favor of treatment.Journal of biopharmaceutical statistics · 2024Article
- Causal inference with recurrent and competing events.Lifetime data analysis · 2024Article
- Article
- Article
- Making Sense of Composite Endpoints in Clinical Research.Journal of clinical medicine · 2023Review
- Inverse Probability Weighting to Estimate Exposure Effects on the Burden of Recurrent Outcomes in the Presence of Competing Events.American journal of epidemiology · 2023Article
- On restricted mean time in favor of treatment.Biometrics · 2023Article
- Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints.Statistics in biopharmaceutical research · 2023Article
- Rationale and design of a randomised trial of intravenous iron in patients with heart failure.Heart (British Cardiac Society) · 2022Article
- On recurrent-event win ratio.Statistical methods in medical research · 2022Article
- Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction.Scientific reports · 2022Article
- Time spent outside of the hospital, CKD progression, and mortality: a prospective cohort study.International urology and nephrology · 2021Article
- Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22927554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.